Dr Elena Castro (Hospital Universitario 12 de Octubre, Madrid, Spain), Dr Pasquale Rescigno (Newcastle University, Newcastle, UK), Prof Gert Attard (University College London Cancer Institute, UK) and Dr Axel Heidenreich (University Hospital Cologne, Cologne,Germany) discuss best practice in precision medicine for prostate cancer.

The panel explores how personalised medicine is transforming prostate cancer care.

They talk about the latest clinical trial data on targeted agents, PARP inhibitors, AR pathway inhibitors, and immunotherapy.

They also cover strategies for patient-tailored treatment selection in mHSPC and biochemically recurrent disease, the critical role of early and timely testing, including genomic and molecular diagnostics for treatment guidance and designing care pathways that prioritise patient outcomes, quality of life, and long-term disease control.